# Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

> **NCT05422508** · PHASE2 · RECRUITING · sponsor: **Green Cross Corporation** · enrollment: 230 (estimated)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** MG1111 (BARICELA)
- **BIOLOGICAL:** VARIVAX
- **BIOLOGICAL:** Suduvax

## Key facts

- **NCT ID:** NCT05422508
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-05
- **Primary completion:** 2025-06
- **Final completion:** 2027-06
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422508, "Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05422508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*